The aim of this study was to assess the acute effects of clonazepam and clonidine on rhythmic masticatory muscle activity in young adults with primary sleep bruxism, as well as accompanying effects on sleep architecture and cardiac activity. This study used a double-blind, crossover, placebo-controlled design. Polysomnography was performed on 19 subjects [nine men and 10 women; mean age (AESE): 25.4 AE 2.7 years] for 5 nights. The first 2 nights were used for the habituation and diagnosis of sleep bruxism. The other 3 nights were randomly assigned for clonazepam (1.0 mg), clonidine (0.15 mg) or placebo (all administered 30 min before bedtime). Sleep, oromotor activity and cardiac activity variables were assessed and compared among the three drug conditions. Clonidine significantly reduced the median percentage of time spent in the rapid eye movement sleep stage compared with placebo and clonazepam. The number of rhythmic masticatory muscle activity episodes was reduced with clonidine by >30% compared with placebo and clonazepam. The reduction of rhythmic masticatory muscle activity index by clonidine was associated with an increase of mean RR intervals (slower heart rate) during quiet sleep periods and during a 70-s period before the onset of rhythmic masticatory muscle activity episodes. However, no changes in cardiac activity variables were observed for clonazepam. In young adults with primary sleep bruxism, clonidine was significantly more effective in suppressing sleep bruxism than clonazepam. The acute effects of clonidine on rhythmic masticatory muscle activity episodes may be mediated by suppression of autonomic nervous system activity and nonrapid eye movement-rapid eye movement sleep processes.
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IN TROD UCTI ON
Sleep bruxism (SB) is classified, by the International Classification of Sleep Disorders third edition, as a sleep-related movement disorder characterized by grinding and clenching of the teeth during sleep (American Academy of Sleep Medicine, 2014). On average, patients with SB exhibit three times the number of rhythmic jaw motor episodes [such as rhythmic masticatory muscle activity (RMMA)] compared with those without SB (Rompr e et al., 2007) . Recent evidence on the pathophysiology of SB indicates that SB is characterized by an increased responsiveness of the jaw motor system to cyclic fluctuations of arousals under a physiological sequence of transient arousal phenomena (Carra et al., 2010; Kato et al., 2001 ). An increased number of RMMA episodes during sleep in patients with SB is considered a risk ª 2016 European Sleep Research Society factor for a number of orodental problems (Kato et al., 2013; Lavigne et al., 2011) . Therefore, several conservative management strategies, including cognitive behavioural therapy and occlusal splint, have been proposed to manage SB for controlling jaw motor activity related to SB and the associated overloads to orodental structures (Carra et al., 2012; Lavigne et al., 2011) . Nonetheless, only limited therapeutic effects on jaw motor activity were reported (Manfredini et al., 2015) .
Several controlled trials have investigated the efficacy of medications in treating SB (Carra et al., 2012) . Among the drugs tested, studies have demonstrated that clonazepam and clonidine have suppressing effects on SB. Clonazepam, a benzodiazepine, has been shown to decrease jaw motor events by 40% in older than middle-aged patients with secondary SB with insomnia and sleep-related movement disorders (Saletu et al., 2005 (Saletu et al., , 2010 . In a mechanistic study, the a 2 -receptor agonist clonidine was found to reduce jaw motor events by 60% in young patients with primary SB (i.e. no concomitant sleep and medical disorders; Huynh et al., 2006) . These findings suggest that these two drugs can be potential therapeutic agents for controlling SB. However, they have distinct mechanisms of action on sleep and motor systems. In addition, the study sample tested in the two studies differed for age and type of SB patients (i.e. primary and secondary SB). The effects of the two drugs on SB need to be confirmed in the same study sample by the randomized clinical trials.
Therefore, in this study, we conducted a double-blind, crossover, placebo-controlled study to compare the effects of clonazepam and clonidine on SB in individuals with primary SB (i.e. no co-morbid medical or sleep problems) using polysomnography (PSG).
MATERI ALS AND METHODS

Subjects
Twenty healthy adults [nine men and 11 women; mean age (AESE): 26.5 AE 2.5 years] were selected from among the students and staff of the Showa University School of Dentistry. Inclusion criteria were: (1) reports of tooth-grinding sounds by a subject's bed partner for at least 3 nights a week during the preceding 6 months (American Academy of Sleep Medicine, 2014; Lavigne et al., 2011) ; and (2) the presence of tooth attrition with dentin exposure on at least three occlusal surfaces (Lavigne et al., 1991) . Exclusion criteria were: (1) two or more missing molars (excluding third molars) or use of a removable prosthesis; (2) use of medication(s); (3) ongoing dental therapy; and (4) neurological, psychiatric and concomitant sleep disorders. For inclusion, subjects needed to fulfill a PSG diagnostic criteria of SB: (1) four or more RMMA episodes per hour of sleep; (2) 25 or more electromyogram (EMG) bursts per hour of sleep; or (3) two or more RMMA episodes during the night with tooth-grinding noise (Rompr e et al., 2007) . This study was approved by the Ethics Committee of Showa University School of Dentistry (no. 2010-025) . Informed consent was obtained from the study subjects prior to their enrollment in the study.
On the basis of a preliminary study, the mean RMMA index for SB subjects was 3.0, with a standard deviation of 2.5. On the basis of the results from a previous study (Yoshizawa et al., 2014) , an improvement of 1.5 in the RMMA index was expected after clonidine or clonazepam administration. A sample size of 15 subjects per group was required to detect this change, assuming a risk of 5% (a = 0.05) and a power of 80% (b = 0.20). After considering the possibility of dropouts, 20 subjects were recruited for this study.
PSG recordings
Polysomnographic recordings were performed for 5 nights at the Showa University School of Dentistry sleep laboratory (Fig. 1) . On the first night, a subject was allowed to adapt to the laboratory setting. The second night was used for the diagnosis and the baseline value. If the PSG data from the second night did not meet the criteria (identified in 'Subjects'), the subject was excluded from further participation. On nights 3, 4 and 5, recordings were made after a subject had taken her/his respective medication or placebo.
On each night, the subject arrived at the sleep laboratory at 21:30 hours. The subject went to bed at 22:30 hours and was awoken at 06:00 hours. On nights 3, 4 and 5, the subjects took their medication or placebo 30 min before going to bed. PSG equipment (Embla N7000, Kanata, Ontario, Canada) was used to record the following biosignals: electroencephalograms (EEGs; C 2 A 1 , C 3 A 2 , O 2 A 1 , O 3 A 2 , F 2 A 1 and F 3 A 2 ); electro-oculograms; electrocardiograms; EMGs of the chin/suprahyoid, bilateral masseter, temporalis and tibialis muscles; snoring sound; nasal pressure; chest and abdominal movements; arterial oxygen saturation; body position; and laryngeal movements. Audio-video recordings were made simultaneously.
Medications
Clonazepam (1.0 mg), clonidine (0.15 mg) and placebo were prepared in the same manner, and placed in capsules that were visually indistinguishable. A previous study showed significant side-effect (20% subjects reported hypotension) from clonidine (0.30 mg). Therefore, in this study we examined the effect of clonidine in smaller dose than in the previous study (Huynh et al., 2006) . As previous studies that tested clonazepam (1.0 mg) reported no significant side-effects, we used the same dosage as these studies (Saletu et al., 2005 (Saletu et al., , 2010 . Subjects received an oral dose of their respective medication or placebo 30 min before bedtime. A minimum 2-week interval was observed between doses to avoid any medication carry-over effects. Six patterns were used for the order in which the medications or placebo were administered on the three experimental nights (nights 3, 4 and 5; Fig. 1 ). The subjects were randomly assigned to one of these six patterns using a Latin square design. The allocation table for All subjects (n = 19) 
Sleep variables
According to the American Academy of Sleep Medicine guidelines (Iber et al., 2007) , sleep stages were scored for each 30-s epoch by a sleep technician (FK). Periodic leg movements during sleep (PLMS), and apnea and hypopnea events were scored: these two variables were not included in our analysis because the PLMS index and the apneahypopnea index were determined to be 0.4 (0.0-3.8) and 1.2 (0.0-3.7), respectively. Microarousal was scored as an abrupt shift in EEG frequency (3-10 s) without complete awakening, and the frequency per hour of sleep was calculated as microarousal index.
Oromotor variables
Oromotor activity was scored using EMG and audio-video recordings, and classified into RMMA episodes and other orofacial activity (e.g. coughing, sleep-talking; Dutra et al., 2009 
Cardiac activity variables
Systolic and diastolic blood pressure was measured using a digital blood-pressure monitor (Omron HEM-7310-IT, Tokyo, Japan) upon waking. The mean RR interval was calculated for 3-min quiet sleep periods (absence of any motor activity, such as body or oromandibular movements) during non-rapid eye movement (NREM) sleep (N2 and N3) and rapid eye movement (REM) sleep. The mean RR interval for 10-s periods was calculated during the 70-s period before the onset of RMMA episodes during stage N2.
Orofacial symptoms and medication side-effects
Subjective orofacial symptoms such as fatigue or pain in the temporomandibular joint or masticatory muscles and tooth discomfort were recorded upon waking in the morning. To assess medication side-effects, sleep quality, mouth dryness, and dizziness upon waking in the morning and during the day were recorded for 3 days after the three experimental nights.
Statistical analysis
Sleep and oromotor activity variables, morning blood pressure and mean RR intervals were compared among the three Cary, NC, USA) was used for all statistical analyses, with the level of significance set at P < 0.05.
RESUL TS Sleep and oromotor variables
Out of 20 subjects initially recruited, one (female, age 26 years) did not meet the PSG diagnostic criteria for SB and was excluded from further recording. In the 19 remaining subjects, the median percentage of REM stage sleep was significantly lower with clonidine (7.1%) than that observed with clonazepam (14.7%) or placebo (16.7%; P < 0.001; Table 1 ). The mean (AESE) percentage of N2 stage sleep was significantly higher with clonidine (57.9 AE 9.1%) compared with placebo (51.5 AE 8.4%; P < 0.05). The mean percentage of N2 stage sleep with clonazepam (53.8 AE 4.5) did not differ from that observed with placebo. No differences were found among the 3 nights for the other sleep variables examined. Although the total number of RMMA episodes and RMMA index values were lowest with clonidine (compared with clonazepam and placebo), these decreases were not statistically significant (Table 1) . When the mean of RMMA index ratio (a value that normalizes index values to baseline data) was assessed, it was significantly lower with clonidine (0.44 AE 0.2) than with clonazepam (0.80 AE 0.3) and placebo (0.72 AE 0.3; P < 0.001). The total number of EMG bursts and the EMG burst index were significantly lower with clonidine than with clonazepam (P < 0.05), but those with clonidine did not differ significantly from those with placebo.
Clonidine responders and non-responders
According to the responses to clonidine, the subjects could be divided into two groups based on the cut-off of ≥25.3% decrease in the RMMA index (Huynh et al., 2006) : 10 were responders (six mild and four moderate-to-severe level of SB) and nine were non-responders (six mild and three moderate-to-severe level of SB).
In the responder group, the mean percentage of REM sleep was significantly lower with clonidine (6.0 AE 6.0%) than with clonazepam (14.9 AE 2.7%) and placebo (14.9 AE 7.2%; P < 0.05; Table 2 ). No significant differences were found for other sleep variables in the clonidine responders ( Table 2 ). The numbers of RMMA episodes, RMMA index values, RMMA index ratios, total numbers of EMG bursts, and the numbers of EMG bursts per hour were significantly lower with Clonidine non-responders (n = 9)
Baseline
(1) Placebo (2) clonidine than with clonazepam or placebo (P < 0.05; Table 2 ). In the non-responder group, no significant differences were found in sleep and oromotor variables, except for the mean percentage of REM stage sleep, which was lower with clonidine (8.7 AE 4.4%) than with placebo (15.7 AE 4.2%; P < 0.05; Table 2 ).
Effects on morning blood pressure
Systolic blood pressure on waking was significantly lower with clonidine than with clonazepam or placebo (P < 0.05), while diastolic blood pressure on waking was significantly lower with clonidine than with placebo (P < 0.05), but not clonazepam (Table 3 ). For responders, systolic blood pressure was significantly lower with clonidine than with clonazepam or placebo (P < 0.01; Table 3 ). Non-responders did not show statistically significant changes in blood pressure by the two medications and placebo.
RR intervals during sleep
Mean RR intervals during quiet NREM sleep periods (N2 and N3) were not significantly different among the 3 nights (Table 4) . Clonidine responders showed significantly longer mean RR intervals during NREM sleep with clonidine compared with those subjects treated with clonazepam or placebo, while no significant changes were found in nonresponders across the 3 nights (P < 0.05; Table 4 ).
Time-course changes of RR intervals before the RMMA onset
Regardless of medication or placebo, mean RR intervals showed a similar pattern of time-course changes during a 70-s period before the onset of RMMA episodes during N2. For all three treatments, mean RR intervals significantly decreased for the 10-s period immediately prior to RMMA (Fig. 2a) . Pairwise comparisons between the medications or placebo revealed that mean RR intervals were significantly longer with clonidine during the period 70-40 s before onset than with clonazepam (P < 0.01; Fig. 2a ). Clonidine responders showed significantly longer mean RR intervals prior to RMMA onset with clonidine than with clonazepam or placebo (Fig. 2b) , while non-responders did not show any statistically significant difference among the 3 nights (Fig. 2c) .
Placebo effects
As shown in Table 1 , all oromotor variables decreased from the baseline night to the placebo night. RMMA index values were significantly lower with placebo compared with those at baseline (P < 0.001; Table 1 ). Sleep variables (Table 1) , morning blood pressure values (Table 3 ) and RR intervals (Table 4) did not differ between the 2 nights. The same results were found for both clonidine responders and nonresponders (Tables 2-4) . Mean RR intervals for 10-s periods were plotted. Abscissa indicates time (in 10-s periods) prior to the onset of RMMA episodes. (a) All subjects (n = 19). † Significant difference between clonidine and clonazepam during a 10-s time period before the onset of RMMA episodes (P < 0.01). (b) Clonidine responders (n = 10). § Significant difference between clonidine and clonazepam or placebo during a 10-s period before the onset of RMMA episodes (P < 0.01). (c) Clonidine non-responders (n = 9). For all panels: no significant difference among the three medications during all periods before onset.
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Clinical symptoms and side-effects On the morning after the baseline night, seven of 19 subjects reported jaw fatigue, jaw pain and tooth discomfort. With the medications or placebo, three subjects with mild SB (including two clonidine responders) reported improvements in these symptoms in the morning after all three experimental nights. No subjects complained of poor sleep quality or daytime sleepiness after any of the three experimental nights. Three subjects (15.8%) reported mouth dryness in the morning after clonidine intake. However, no subjects exhibited symptomatic morning hypotension. Two subjects (10.5%) complained of dizziness after taking clonazepam.
DI SCUSSION
Using a double-blind, crossover, placebo-controlled randomized clinical trial, clonidine was found to significantly decrease the RMMA index ratio compared with clonazepam and placebo. The effects of clonidine on SB were associated with a significant decrease in the percentage of REM sleep and an increase of mean RR interval during NREM sleep. These results suggest that clonidine is more effective in decreasing primary SB compared with clonazepam.
Clonidine
In this study, the effects of clonidine on the number of RMMA episodes (>30%) were moderate compared with a previous randomized, controlled, double-blind study (60%; Huynh et al., 2006) . In our study, 52.6% of the subjects were classified as clonidine responders according to the cut-off criterion of ≥25.3% for SB suppression (Huynh et al., 2006) . This proportion was lower than that found in the previous study (80% ; Huynh et al., 2006) . The discrepancy between the results of two studies may be attributed to the difference in the doses used and the dose-dependent effects on the sleep and autonomic nervous systems. Clonidine acts on central a 2 receptors to decrease tension in sympathetic nervous tone and lower blood pressure. It also acts on the REM sleep generator to suppress REM sleep (Gentili et al., 1996) . Similar to previous studies, our results showed that clonidine significantly decreased the percentage of REM sleep by approximately 50% and systolic blood pressure in the morning by approximately 10%. However, these effects were not as marked as the decreases observed in a previous study (approximately 100% for REM sleep and 20% for blood pressure) that used larger doses of the drug (Huynh et al., 2006) . Therefore, the effects of clonidine on SB may well be dependent on the dosage, which may need a medical supervision ideally.
Autonomic activity
Similar to previous studies, we observed a decrease in RR intervals before the onset of RMMA episodes, regardless of the use of medication or placebo (Huynh et al., 2006) . However, clonidine responders differed from non-responders in terms of a suppression of autonomic functions. The effects of clonidine in responders included decreased cardiac activity not only during 3-min quiet periods for sleep stages, but also during the 70-s period prior to the onset of an RMMA episode. Studies have shown that movement generation during sleep such as SB and PLMS requires sequential hierarchial patterns of microarousals from autonomic, cortical and motor activity (Kato et al., 2011; Sforza et al., 2002) . However, no differences were observed in the number of microarousals between the clonidine responders and non-responders. Therefore, clonidine-induced decrease in sympathetic activity may alter the characteristics of the arousal hierarchy, thereby suppressing increased responsiveness of stereotypical phasic movement (such as RMMA). Although the possibility of clonidine directly acting on the trigeminal motor system must be considered (Katakura and Chandler, 1991) , the results of the present study suggest that the central effect of clonidine on the autonomic nervous system is the main factor for suppressing SB.
Clonazepam
Clonazepam failed to show the positive effects on SB and modify sleep architecture in our study sample. However, in previous placebo-controlled studies, the same dose of clonazepam significantly decreased oromotor activity in patients with middle-aged secondary SB (with insomnias, periodic leg movements and restless legs syndrome) in association with improved sleep continuity (Saletu et al., 2005 (Saletu et al., , 2010 . Clonazepam is an anticonvulsant that can modulate cortical excitability during sleep through c-aminobutyric acid (GABA) A receptors (Manconi et al., 2012) . Although controversial, several studies have shown that clonazepam has only mild decreasing effects on sleeprelated abnormal movements (i.e. restless leg syndrome and periodic leg movements), but improves sleep fragmentation (Manconi et al., 2012) . Using a crossover design, the present study showed that clonazepam did not modify cardiac and autonomic activities as well as the occurrence of microarousals and RMMA episodes in primary SB. Our results support the recent proposal that arousal activities provide a permissive window, rather than a trigger, for the genesis of RMMA (Carra et al., 2010; Kato et al., 2003) . Therefore, a more likely interpretation for non-significant effects of clonazepam on SB is that the genesis of RMMA episodes can be more influenced by the modulation of autonomic activity rather than cortical arousal activities in primary SB.
Placebo effects
Another important finding of the present study was a small but statistically significant placebo effect on SB: RMMA index values were 28% lower with placebo compared with those at ª 2016 European Sleep Research Society baseline (Table 1) . More than 50% of our subjects (n = 10) showed a decrease larger than the inter-day variability of RMMA index (i.e. 25%; Lavigne et al., 2001b) . More interestingly, no difference between baseline and placebo nights was noted for blood pressure values, RR intervals during quiet sleep, or time-course changes in RR intervals prior to an RMMA episode. A similar placebo effect on RMMA episodes was observed among both clonidine nonresponders and responders (Table 2) . Therefore, the placebo effect observed in the present study may have been due to one or more factor(s) distinct from the variables that we analyzed. There might be possibility of the Hawthorne effect, suggestive effects or expectations resulting from the accurate explanations and instructions regarding the medications resulted in the placebo effects observed in our study (Enck et al., 2013) . The potential significance of placebo effects needs to be investigated in future studies.
Limitations
The subjects in the present study were selected according to the presence of tooth-grinding noise during sleep and occlusal attrition. These criteria were selected because they may be clinical signs of the presence of phasic episodes (Yoshizawa et al., 2014) . However, because few of these subjects had orofacial symptoms upon waking at baseline, it was difficult to assess the degree to which the SBsuppressive effects of clonidine alleviated their clinical symptoms. Moreover, we examined subjects with mild to severe SB, whereas previous studies only examined subjects with severe SB (Huynh et al., 2006) . Nonetheless, we found that SB-suppressive effects of clonidine were associated with effects on cardiac activity and REM sleep, suggesting the importance of autonomic regulation and NREM/REM sleep processes in the genesis of RMMA (Carra et al., 2010) . The subjects of this study reported few side-effects with an acute administration of drugs. However, we assessed the side-effects only in the morning. Because clonidine and clonazepam have a wide-range of side-effects that were not systemically investigated in this study (Kenndy and Lhatoo, 2008; Van Zwieten et al., 1984) , the use of these medications needs medical supervision. The present proof-of-concept study was done in a small sample. Therefore, larger-sample studies are needed to differentiate the agents before ascertaining the effectiveness of these agents. Individual difference in drug responsiveness (efficacy and side-effects) can be affected by pathophysiological (e.g. sleep disorders) and genetic (e.g. genetic polymorphisms that encode drug metabolism enzymes or transporters) factors (Brockm€ oller and Tzvetkov, 2008) . Taken together, further clinical trials examining longer-term use will be needed to determine individual differences in sensitivity to these medications, as well as any placebo effects, in order to establish personalized management strategies for SB.
CONC LUSIONS
Clonidine was significantly more effective in suppressing SB compared with clonazepam. The effects of clonidine on SB may be mediated by suppression of autonomic nervous system activity. However, individual differences and concomitant placebo effects can be expected with the acute use of clonidine.
